Notes on the Preclinical Development of Imbruvica (Ibrutinib)
Government Funded research
KEI Comments on NIH License to EnZeta Immunotherapies for Solid Tumors
On August 28, 2023, Knowledge Ecology International (KEI) provided comments to the National Institutes of Health (NIH) objecting to the “Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors” (88 FR… Continue Reading
KEI August 18, 2023 Comments to the NIH licensing practices highlight failure to enforce Section 209 restrictions on exclusivity, transparency concerns, and KEI’s past engagement
As a part of the workshop hosted by the National Institutes of Health (NIH) on July 31, 2023 on the topic of, “Transforming Discoveries Into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer,” the NIH solicited public comments. In addition… Continue Reading
KEI Exchange with the NIH Regarding April 2023 EnZeta Prospective License Notice
KEI recently submitted comments to the National Institutes of Health (NIH) regarding its drastic cuts in the length of public comment periods for proposed exclusive licenses. In our comments, KEI discussed reasons that a longer comment period is important for… Continue Reading
KEI Comment on the Reduction of Number of Days the Public Can Comment on a Prospective NIH Exclusive Patent License
The National Institute of Health (NIH) recently held an all-day workshop titled, “Transforming Discoveries Into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.” KEI Director James Love participated in the July 31st workshop, speaking on the panel on “How NIH… Continue Reading
The NIH has radically reduced the time for the public to comment on exclusive licenses
KEI Questions to the NIH Regarding Prospective License of T-cell Cancer Therapy to EnZeta Immunotherapies
(Update: The NIH provided a response to our questions on August 17, 2023.) On August 11, 2023, Knowledge Ecology International (KEI) submitted questions to the National Institutes of Health regarding the “Prospective Grant of an Exclusive Patent License: Manufacture, Distribution,… Continue Reading
KEI Comments to the NIH Regarding the Prospective Grant of an Exclusive License to Elgia Therapeutics
On Friday August 4, 2023, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Caspase Inhibitors” (88 FR 47152) to Elgia Therapeutics, Inc.… Continue Reading
KEI Comments on draft 2023 Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)
KEI provided these comments to the Senate HELP Committee staff on July 10, 2023, regarding a draft bill dealing with pandemic preparation and response. The specific issue KEI was asked to comment on concerned the proposal by Senator Sanders for… Continue Reading
WHA76: KEI statement on Strengthening WHO preparedness for and response to health emergencies
On Wednesday, 24 May 2023, Knowledge Ecology International (KEI) delivered a statement at the 76th World Health Assembly on Strengthening WHO preparedness for and response to health emergencies. WHO member states should make negotiations at the INB on a pandemic… Continue Reading